Pierrel S.p.A. entered into agreements to acquire from 3M Company contracts, permits and intellectual property related to the local anaesthesia dental products, together with related syringe and needle products, under the brands Ubistesin™, Xylestesin™ and Mepivastesin™ for a purchase price of USD 70 million
• The acquisition will expand Pierrel’s presence globally with branded products by complementing its own-brand dental anesthetics Orabloc’s offering, bringing more solutions to Pierrel’s customers.
• Pierrel’s revenues for FY 2024 is expected to double compared to the estimated revenues for the current year.
